Balchem Corporation (BCPC)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ
Market Cap: $5.52B
Last updated: Nov 17, 2026 at 11:04 AM ET
Balchem Corporation (BCPC) Earnings: Report Dates and Results
Balchem (BCPC) is expected to report earnings on Feb 18, 2027. In the quarter ended Sep 30, 2026, Balchem reported EPS of $1.57, above the $1.54 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BCPC has an expected report date of Feb 18, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.7% above the $1.31 reported for the quarter ended Dec 31, 2025.
BCPC Earnings Call
The latest BCPC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BCPC beat 32, missed 3 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $290.66M, up 8.6% from $267.56M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.57 | $1.54 | $1.51 - $1.56 | +1.95% | Beat | +16.3% | 2 | 2 up, 0 down | Oct 23, 2026 | $290.66M |
| Jun 30, 2026 | $1.49 | $1.40 | N/A | +6.43% | Beat | +17.3% | 2 | 1 up, 0 down | Jul 31, 2026 | $284.00M |
| Mar 31, 2026 | $1.33 | $1.33 | $1.32 - $1.34 | 0.00% | In line | +9.0% | 2 | 2 up, 0 down | Apr 30, 2026 | $270.71M |
| Dec 31, 2025 | $1.31 | $1.18 | N/A | +11.02% | Beat | +15.9% | 2 | 1 up, 1 down | Feb 20, 2026 | $263.62M |
| Sep 30, 2025 | $1.35 | $1.31 | $1.26 - $1.36 | +3.05% | Beat | +19.5% | 2 | 0 up, 1 down | Oct 21, 2025 | $267.56M |
| Jun 30, 2025 | $1.27 | $1.25 | $1.25 - $1.25 | +1.60% | Beat | +16.5% | 2 | 0 up, 2 down | Jul 31, 2025 | $255.47M |
| Mar 31, 2025 | $1.22 | $1.22 | $1.18 - $1.25 | 0.00% | In line | +18.4% | 2 | 1 up, 0 down | Apr 24, 2025 | $250.52M |
| Dec 31, 2024 | $1.13 | $1.11 | $1.10 - $1.11 | +2.26% | Beat | +18.9% | 2 | 0 up, 2 down | Feb 21, 2025 | $240.00M |
| Sep 30, 2024 | $1.13 | $1.12 | $1.10 - $1.12 | +0.89% | Beat | +8.7% | 2 | 0 up, 0 down | Oct 25, 2024 | $239.94M |
| Jun 30, 2024 | $1.09 | $1.03 | $1.03 - $1.04 | +5.83% | Beat | +2.8% | 2 | 1 up, 0 down | Jul 26, 2024 | $234.08M |
| Mar 31, 2024 | $1.03 | $0.98 | $0.98 - $0.98 | +5.10% | Beat | +9.6% | 2 | 0 up, 0 down | May 3, 2024 | $239.66M |
| Dec 31, 2023 | $0.95 | $0.93 | $0.85 - $1.01 | +2.15% | Beat | +1.1% | 2 | 0 up, 0 down | Feb 16, 2024 | $228.70M |
| Sep 30, 2023 | $1.04 | $0.97 | $0.89 - $1.05 | +7.22% | Beat | +4.0% | 2 | 0 up, 0 down | Oct 27, 2023 | $229.95M |
| Jun 30, 2023 | $1.06 | $0.93 | $0.75 - $0.93 | +13.98% | Beat | -0.9% | 2 | 0 up, 0 down | Jul 28, 2023 | $231.25M |
| Mar 31, 2023 | $0.94 | $0.82 | N/A | +14.63% | Beat | -8.7% | 2 | 0 up, 0 down | Apr 28, 2023 | $232.54M |
| Dec 31, 2022 | $0.94 | $0.83 | $0.69 - $0.91 | +13.25% | Beat | +10.6% | 3 | 0 up, 0 down | Feb 24, 2023 | $232.53M |
| Sep 30, 2022 | $1.00 | $1.03 | N/A | -2.91% | Miss | +8.7% | 3 | 0 up, 0 down | Nov 4, 2022 | $244.27M |
| Jun 30, 2022 | $1.07 | $1.00 | $1.00 - $1.00 | +7.00% | Beat | +15.1% | 1 | 0 up, 0 down | Jul 29, 2022 | $236.69M |
| Mar 31, 2022 | $1.03 | $0.92 | $0.72 - $0.92 | +11.96% | Beat | +18.4% | 2 | 0 up, 0 down | Apr 29, 2022 | $228.87M |
| Dec 31, 2021 | $0.85 | $0.85 | $0.85 - $0.85 | 0.00% | In line | +2.4% | 1 | N/A | Feb 18, 2022 | $213.13M |
| Sep 30, 2021 | $0.92 | $0.94 | $0.90 - $0.98 | -2.13% | Miss | +10.8% | 2 | 0 up, 0 down | Oct 29, 2021 | $197.87M |
| Jun 30, 2021 | $0.93 | $0.88 | $0.84 - $0.92 | +5.68% | Beat | +9.4% | 2 | N/A | Jul 30, 2021 | $202.37M |
| Mar 31, 2021 | $0.87 | $0.85 | $0.79 - $0.90 | +2.35% | Beat | +7.4% | 2 | N/A | Apr 30, 2021 | $185.66M |
| Dec 31, 2020 | $0.83 | $0.81 | $0.76 - $0.85 | +2.47% | Beat | -5.7% | 2 | N/A | Feb 19, 2021 | $180.71M |
| Sep 30, 2020 | $0.83 | $0.78 | $0.61 - $0.79 | +6.41% | Beat | +2.5% | 2 | N/A | Oct 28, 2020 | $175.14M |
| Jun 30, 2020 | $0.85 | $0.55 | $0.55 - $0.57 | +54.55% | Beat | +10.4% | 2 | N/A | Jul 31, 2020 | $173.35M |
| Mar 31, 2020 | $0.81 | $0.78 | N/A | +3.85% | Beat | +11.0% | 2 | N/A | May 1, 2020 | $174.44M |
| Dec 31, 2019 | $0.88 | $0.84 | $0.84 - $0.84 | +4.76% | Beat | +14.3% | 1 | N/A | Feb 21, 2020 | $166.53M |
| Sep 30, 2019 | $0.81 | $0.74 | $0.74 - $0.74 | +9.46% | Beat | +11.0% | 1 | N/A | Nov 5, 2019 | $158.59M |
| Jun 30, 2019 | $0.77 | $0.76 | $0.65 - $0.78 | +1.32% | Beat | +1.3% | 2 | N/A | Aug 1, 2019 | $161.55M |
| Mar 31, 2019 | $0.73 | $0.73 | N/A | 0.00% | In line | -3.9% | 2 | N/A | May 3, 2019 | $157.03M |
| Dec 31, 2018 | $0.77 | $0.69 | $0.52 - $0.80 | +11.59% | Beat | +13.2% | 3 | N/A | Feb 28, 2019 | $163.54M |
| Sep 30, 2018 | $0.73 | $0.73 | $0.57 - $0.73 | 0.00% | In line | +15.9% | 2 | N/A | Nov 6, 2018 | $155.04M |
| Jun 30, 2018 | $0.76 | $0.74 | $0.74 - $0.77 | +2.70% | Beat | +18.8% | 2 | N/A | Aug 3, 2018 | $163.69M |
| Mar 31, 2018 | $0.76 | $0.70 | $0.70 - $0.71 | +8.57% | Beat | +28.8% | 2 | N/A | May 4, 2018 | $161.41M |
| Dec 31, 2017 | $0.68 | $0.62 | $0.61 - $0.64 | +9.68% | Beat | +1.5% | 3 | N/A | Feb 27, 2018 | $159.26M |
| Sep 30, 2017 | $0.63 | $0.62 | $0.61 - $0.63 | +1.61% | Beat | +3.3% | 3 | N/A | Nov 7, 2017 | $150.72M |
| Jun 30, 2017 | $0.64 | $0.63 | $0.61 - $0.65 | +1.59% | Beat | -3.0% | 3 | N/A | Aug 4, 2017 | $147.08M |
| Mar 31, 2017 | $0.59 | $0.61 | N/A | -3.28% | Miss | +1.7% | N/A | N/A | May 9, 2017 | $137.73M |
| Dec 31, 2016 | $0.67 | $0.65 | N/A | +3.08% | Beat | +1.5% | N/A | N/A | Feb 28, 2017 | $140.76M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $5.15, up 17.6% from the year before. It was $2.52 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $5.15 | +17.6% |
| Dec 31, 2024 | $4.38 | +9.8% |
| Dec 31, 2023 | $3.99 | -1.2% |
| Dec 31, 2022 | $4.04 | +13.2% |
| Dec 31, 2021 | $3.57 | +7.5% |
| Dec 31, 2020 | $3.32 | +4.1% |
| Dec 31, 2019 | $3.19 | +5.6% |
| Dec 31, 2018 | $3.02 | +18.9% |
| Dec 31, 2017 | $2.54 | N/A |
| Dec 31, 2016 | $2.52 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,200 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,244 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,841 | 6 | |
| 2026Q1 | Mar 31, 2026 | 5,520 | 7 | |
| 2025Q4 | Dec 31, 2025 | 6,595 | 7 | |
| 2025Q3 | Sep 30, 2025 | 5,440 | 6 | |
| 2025Q2 | Jun 30, 2025 | 5,058 | 7 | |
| 2025Q1 | Mar 31, 2025 | 4,585 | 6 | |
| 2024Q4 | Dec 31, 2024 | 5,173 | 6 |
2026Q3 Earnings Call
Opening remarks
Carl Martin Bengtsson CFO Thank you. Good morning, everyone. Thank you for joining our conference call this morning to discuss the results of Balchem Corporation for the quarter ending September 30, 2026. My name is Martin Bengtsson, Chief Financial Officer, and hosting this call with me is Ted Harris, our Chairman, President, and CEO. Following the advice of our counsel, auditors, and the SEC, at this time I would like to read our forward-looking statement. Statements made in today's call that are not historical facts are considered forward-looking statements. We can give no assurance that the expectations reflected in forward-looking statements will prove correct, and various factors could cause actual results to differ materially from our expectations, including risks and factors identified in Balchem's most recent Form 10-K, 10-Q, and 8-K reports. The company assumes no obligation to update these forward-looking statements. Our commentary also includes non-GAAP financial measures. Please refer to the reconciliations in our earnings release for further details. I will now turn the call over to Ted Harris, our Chairman, President, and CEO.
Theodore L. Harris Chairman, President, and CEO Thanks, Martin. Good morning, and welcome to our conference call. We were very pleased with our third-quarter results reported earlier this morning. They were once again driven by healthy, broad-based growth across all three of our reporting segments and continued solid execution on our strategic growth initiatives. Our healthy growth continues to be fueled by the ongoing market penetration of our unique portfolio of specialty nutrients and delivery systems, and the favorable better-for-you trends within the food and nutrition markets that are well aligned with our product offerings and capabilities. As a result, we delivered record quarterly consolidated sales, net earnings, and adjusted EBITDA, as well as solid cash flows. Before discussing our third-quarter financial results in more detail, I would like to provide a few comments on the current market environment within which we are operating, and also provide you with some updates regarding new science that has been recently published supporting our branded ingredients VitaCholine, K2VITAL, and K2VITAL DELTA. We continue to see healthy demand trends across the majority of our businesses. Within human nutrition and health, we continue to see solid demand growth for our unique portfolio of ingredients and solutions. Consumer interest in supplementation and better-for-you food systems continues to support a healthy market environment for us. In animal nutrition and health, momentum continues to build. Both ruminant and monogastric customers continue to adopt our nutrient technologies as they look for cost-effective ways to improve animal health and productivity. Within specialty products, we continue to see healthy market demand for our specialized performance gases and services.
Frequently Asked Questions About BCPC
When is Balchem's next earnings date?
Balchem's next earnings report is expected for Feb 18, 2027.
Did BCPC beat earnings estimates last quarter?
Yes. Balchem reported EPS of $1.57 for the quarter ended Sep 30, 2026, above the $1.54 estimate, a 1.95% surprise.
What EPS do analysts expect from BCPC next quarter?
The consensus EPS estimate for Balchem for the quarter ending Dec 31, 2026 is $1.49 from 5 analysts, with estimates from $1.43 to $1.54.
How often does BCPC beat earnings estimates?
Balchem beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +3.29%.
BCPC pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors